

PRESS RELEASE

Strides Arcolab receives USFDA approval for its Penicillin Sterile Facility in Bangalore

Bangalore, India: 11-Mar-08

Strides Arcolab today announced that its penicillin sterile manufacturing site in Bangalore has been classified as acceptable by the USFDA for manufacturing sterile products for the US market. The facility was approved with no FDA-483 observations.

In a statement, Mr. Arun Kumar – Vice Chairman and Group CEO of Strides Arcolab stated that the USFDA approval of the penicillin sterile facility is an important milestone for the Company's US strategy and will support important product submissions with the FDA.

About the Penicillin Sterile Facility

The penicillin sterile facility in Bangalore manufactures sterile injectables in dry powder vials. The plant supports important current and future submissions for the US market.

About Strides Arcolab Limited

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is one of India's largest exporters of branded generic pharmaceutical products. Strides manufacture pharmaceutical formulations in various dosage forms, including capsules, tablets, liquid injectables and is one of the world's top five manufacturers of soft gel capsules. Strides also have the only globally dedicated soft gel facility for hormones. In addition, Strides undertakes contract research and the manufacturing of specialty chemicals for various multinational companies. Strides has a major presence in various developing countries such as Africa, Latin America and Asia as well as in developed markets such as the US, Canada and part of Europe. Strides is one of the largest Indian suppliers of institutionally funded aid projects and is an approved supplier to the World Bank, the African Development Bank and UNICEF, amongst others.

Strides has 14 manufacturing plants spread across the Brazil, Mexico, Italy, Poland, Singapore and India. This broad manufacturing network facilities partnering with global organizations ranging from UNICEF and WHO-Global Drug Facility to European and American pharmaceutical multinationals and also private labelers and distribution chains. Strides has product registrations in over 37 countries around the world. The Indian manufacturing facilities for the regulated markets are approved by all major regulatory bodies such as MHRA, EU, TGA, MCC and USFDA and GMP accreditations including USFDA. Strides employ approximately 1,700 people across the globe. Strides also have a marketing presence in over 50 countries.

Additional information is available at the Company's website at www.stridesarco.com.



Ka.

For further information, please contact:

<p>Mr. Arun Kumar Vice Chairman & Group CEO</p> <p>Or</p> <p>Mr. Ravi Seth CEO International Operations Strides Arcolab Limited</p> <p>Tel: +91 80 6658 0110 Fax: +91 80 6658 0200</p>	<p>Adfactors PR, Bangalore Ms. Harini Iyengar / Ms. Deepti Iyengar Tel: +91 80 4113 3062 Fax: +91 80 4113 3059</p> <p>Adfactors PR, Mumbai Mr. Rakesh Sharma / Mr. Aryan Rana Tel : +91 22 2281 3565 Fax: +91 22 2281 3569</p>
--	--

